Skip to main content
Publications
Marsal JR , Urreta-Barallobre I, Ubeda-Carrillo M, Osorio D, Lumbreras B, Lora D, Fernandez-Felix BM, Oristrell G, Rodenas-Alesina E, Herrador L, Ballesteros M, Zamora J, Pijoan JI, Ribera A, Ferreira-Gonzalez I. Sample size requirement in trials that use the composite endpoint major adverse cardiovascular events (MACE): new insights . Trials. 2022 Dec 21;23(1):1037. doi: 10.1186/s13063-022-06977-4
Gilbertson DT, Rothman KJ , Chertow GM, Bradbury BD, Brookhart MA, Liu L, Winkelmayer WC, Sturmer T, Monda KL, Herzog CA, Ashfaq A, Collins AJ, Wetmore JB. Excess deaths attributable to influenza-like illness in the ESRD population . J Am Soc Nephrol. 2019 Feb;30(2):346-53. doi: 10.1681/ASN.2018060581
Chertow GM, Liu J, Monda KL, Gilbertson DT, Brookhart MA, Beaubrun AC, Winkelmayer WC, Pollock A, Herzog CA, Ashfaq A, Sturmer T, Rothman KJ , Bradbury BD, Collins AJ. Epoetin alfa and outcomes in dialysis amid regulatory and payment reform . J Am Soc Nephrol. 2016 Oct;27(10):3129-38. doi: 10.1681/ASN.2015111232
Mease P, Arnold LM, Choy EH, Clauw DJ, Crofford LJ, Glass JM, Martin SA , Morea J, Simon L, Strand CV, Williams DA. Fibromyalgia syndrome module at OMERACT 9: domain construct . J Rheumatol. 2009 Oct 1;36(10):2318-29.
Mease P, Arnold LM, Bennett R, Boonen A, Buskila D, Carville S, Chappell A, Choy E, Clauw D, Dadabhoy D, Gendreau M, Goldenberg D, Littlejohn G, Martin SA . OMERACT 8 workshop: fibromyalgia syndrome . J Rheumatol. 2007 Jun;34(6):1415-25.